Reply: Competing risk and surveillance thresholds for HCC in patients with PSC.

Magnus Holmer; Michael Ingre; Martti Färkkilâ; Cyriel Ponsioen; Bregje Mol; Christoph Schramm; Trine Folseraas; Kristine Wiencke; Nora Cazzagon; Elisa Catanzaro; Antonio Molinaro; Emma Nilsson; Johan Vessby; Stergios Kechagias; Nils Nyhlin; Mårten Werner; Annika Bergquist

doi:10.1097/HEP.0000000000001651

← 뒤로

Reply: Competing risk and surveillance thresholds for HCC in patients with PSC.

사설/논평 1/5 보강

Hepatology (Baltimore, Md.) 📖 저널 OA 22.4% 2025~2026 2026 Vol.83(4) p. E123-E124 Hepatocellular Carcinoma Treatment a

OpenAlex 토픽 · Hepatocellular Carcinoma Treatment and Prognosis Hepatitis C virus research Cardiac Imaging and Diagnostics

Holmer M, Ingre M, Färkkilä M, Ponsioen C, Mol B, Schramm C

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Magnus Holmer, Michael Ingre, et al. (2026). Reply: Competing risk and surveillance thresholds for HCC in patients with PSC.. Hepatology (Baltimore, Md.), 83(4), E123-E124. https://doi.org/10.1097/HEP.0000000000001651

MLA Magnus Holmer, et al.. "Reply: Competing risk and surveillance thresholds for HCC in patients with PSC.." Hepatology (Baltimore, Md.), vol. 83, no. 4, 2026, pp. E123-E124.

PMID 41405465 ↗

DOI 10.1097/HEP.0000000000001651

같은 제1저자의 인용 많은 논문 (1)

Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
Hepatology (Baltimore, Md.) 2026